How to Convert 2.5 mg to Units on an Insulin Syringe: A Concentration-Specific Guide

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · Sources listed below

Key Takeaways

• At 10 mg/mL concentration, 2.5 mg equals 25 units on a U-100 insulin syringe (0.25 mL). This is a common concentration, but not a standard.
• The conversion changes with concentration: 50 units at 5 mg/mL, 17 units at 15 mg/mL, and 12.5 units at 20 mg/mL for the same 2.5 mg dose.
• "Units" refers to syringe markings, not medication potency. Compounded GLP-1 medications have no standardized unit measurement like insulin.
• The FDA says it has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide (FDA, content current as of September 1, 2026); reading the wrong concentration or using a non-U-100 syringe are two classic ways that happens

The short answer

For a 2.5 mg dose of compounded semaglutide or tirzepatide, you draw 25 units on a U-100 insulin syringe if your vial is 10 mg/mL. The unit count changes based on your specific vial's concentration. Always verify the mg/mL printed on your vial label before drawing, as different pharmacies use different concentrations.

Table of contents

1. Why the answer depends on your vial's concentration
2. The universal conversion formula (and when it breaks)
3. Complete conversion chart for all common concentrations
4. How to identify your vial's concentration in 10 seconds
5. Step-by-step: drawing 2.5 mg with a U-100 insulin syringe
6. What most articles get wrong about "units"
7. The three failure modes of syringe-based dosing
8. When 2.5 mg isn't actually 2.5 mg (reconstitution errors)
9. U-100 vs. U-40 vs. U-500: why syringe type matters more than you think
10. Storage and stability after first draw
11. When to contact your provider about dose conversion
12. What 2.5 mg looks like in the approved products
13. Syringe scales side by side
14. FDA status and safety reports as of September 5, 2026
15. FAQ

Why the answer depends on your vial's concentration

The phrase "2.5 mg to units syringe" contains an invisible variable: concentration. A milligram (mg) measures mass. A unit on an insulin syringe measures volume (specifically, 0.01 mL per unit on a U-100 syringe). Converting between the two requires knowing how much medication mass is dissolved in each milliliter of liquid.

Compounding pharmacies prepare GLP-1 medications at different concentrations based on vial size, total medication amount, and dispensing protocol. The same 2.5 mg dose occupies different volumes depending on concentration:

• 5 mg/mL: 2.5 mg occupies 0.50 mL (50 units)
• 10 mg/mL: 2.5 mg occupies 0.25 mL (25 units)
• 15 mg/mL: 2.5 mg occupies 0.17 mL (17 units)
• 20 mg/mL: 2.5 mg occupies 0.125 mL (12.5 units)

There is no universal answer. The conversion is pharmacy-specific and vial-specific. Patients switching pharmacies or receiving a new vial formulation must re-check concentration every time.

This is a well-recognized dosing error in compounded GLP-1 therapy: assuming the unit count stays constant across refills. Correction, September 2026: an earlier version cited a 2024 Clinical Toxicology analysis of FAERS data (Patel et al.) with a 42 percent figure; that paper could not be found in PubMed and has been removed. The FDA's own statement is qualitative: it has "received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products" (FDA, content current as of September 1, 2026).

The universal conversion formula (and when it breaks)

The conversion from milligrams to syringe units follows this three-step formula:

1. Divide the dose in mg by the concentration in mg/mL to get volume in mL
2. Multiply the volume in mL by 100 to convert to units on a U-100 syringe
3. Verify the result fits within your syringe's capacity (typically 0.3 mL, 0.5 mL, or 1.0 mL)

Example: 2.5 mg dose at 10 mg/mL concentration

• 2.5 mg ÷ 10 mg/mL = 0.25 mL
• 0.25 mL × 100 = 25 units

The formula breaks in three scenarios:

Scenario 1: Reconstituted vials without final concentration labeled. Some pharmacies ship lyophilized (freeze-dried) powder with separate bacteriostatic water. The concentration depends on how much water you add. If instructions say "add 2 mL of water to 10 mg powder," the final concentration is 10 mg ÷ 2 mL = 5 mg/mL. If you add 3 mL by mistake, concentration drops to 3.33 mg/mL, and your unit count is wrong.

Scenario 2: Non-U-100 syringes. The "multiply by 100" step assumes a U-100 insulin syringe where 1 unit = 0.01 mL. U-40 syringes (1 unit = 0.025 mL) and U-500 syringes (1 unit = 0.002 mL) use different scales. Drawing "25 units" on a U-500 syringe delivers one-fifth the intended dose.

Scenario 3: Combination vials. Some compounding pharmacies mix semaglutide or tirzepatide with vitamin B12, L-carnitine, or other additives. If the label says "semaglutide 5 mg/mL + cyanocobalamin 0.5 mg/mL," the semaglutide concentration is still 5 mg/mL. The B12 doesn't change the GLP-1 math. But if the label only says "total peptide 5.5 mg/mL," you can't calculate semaglutide dose without knowing the ratio.

Complete conversion chart for all common concentrations

The table below covers every concentration you're likely to encounter from a U.S. compounding pharmacy for semaglutide or tirzepatide. All volumes assume a U-100 insulin syringe.

Concentration	0.25 mg	0.5 mg	1.0 mg	2.5 mg	5.0 mg	7.5 mg	10 mg	12.5 mg	15 mg
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)	250 units (2.50 mL)	300 units (3.00 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
12.5 mg/mL	2 units (0.02 mL)	4 units (0.04 mL)	8 units (0.08 mL)	20 units (0.20 mL)	40 units (0.40 mL)	60 units (0.60 mL)	80 units (0.80 mL)	100 units (1.00 mL)	120 units (1.20 mL)
15 mg/mL	1.7 units (0.017 mL)	3.3 units (0.033 mL)	6.7 units (0.067 mL)	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)
25 mg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)	10 units (0.10 mL)	20 units (0.20 mL)	30 units (0.30 mL)	40 units (0.40 mL)	50 units (0.50 mL)	60 units (0.60 mL)

Key observations:

• 10 mg/mL gives the simplest math because every milligram converts to exactly 10 units. It is common but not universal: one dose calculator lists 2.5 and 5 mg/mL as typical semaglutide concentrations and 17 and 20 mg/mL for tirzepatide (Rivas Weight Loss, March 2026), while a Victor, New York pharmacy's October 2024 patient sheet uses 10 mg/mL for tirzepatide.
• 5 mg/mL produces larger injection volumes. A 2.5 mg dose is 50 units (0.5 mL), which fills most of a 0.5 mL syringe barrel. Some patients prefer this because the larger volume is easier to read accurately.
• 20 mg/mL and 25 mg/mL are used for high-dose patients (10 mg and above) to keep injection volume small. A 15 mg dose at 25 mg/mL is only 60 units (0.6 mL) versus 150 units (1.5 mL) at 10 mg/mL.
• 15 mg/mL creates fractional unit counts (17 units, 33 units, 67 units) that are harder to draw accurately on syringes without half-unit markings. Most pharmacies avoid this concentration unless space-constrained.

How to identify your vial's concentration in 10 seconds

Concentration appears in one of four places, in order of reliability:

1. Vial label, primary panel. Look for "X mg/mL" printed near the medication name. Example: "Semaglutide Injection 10 mg/mL." This is the concentration.

2. Vial label, secondary panel. Some pharmacies print total contents as a fraction: "50 mg / 5 mL." Divide the numerator by the denominator: 50 ÷ 5 = 10 mg/mL.

3. Pharmacy dispensing instructions. The paper insert or patient portal message includes a dosing table. The header row shows concentration. Example: "Each 0.25 mL (25 units) contains 2.5 mg semaglutide (10 mg/mL concentration)."

4. Prescription label on the box. The outer packaging sometimes lists concentration in the auxiliary information section.

If concentration doesn't appear in any of these four places, the label is missing information that USP <797> labeling requirements call for. Call the pharmacy before drawing a dose.

Common label formats that confuse patients:

• "Semaglutide 5 mg" with no volume listed. This is incomplete labeling. The concentration could be 5 mg/mL, 10 mg/mL, or anything else depending on the total volume.
• "Semaglutide for injection, 2.5 mg/0.5 mL per dose." This describes one dose, not the vial's concentration. If the vial contains multiple doses, you need the total mg and total mL to calculate concentration.
• "Compounded semaglutide, see insert for dosing." The concentration is in the insert, not on the vial. Keep the insert with the vial.

Correction, September 2026: an earlier version cited a 2025 survey of 340 compounding pharmacies (Johnson et al.) reporting that 18 percent of vials lacked a concentration on the label. That survey could not be found in PubMed and has been removed. The practical advice is unchanged: if you cannot find the concentration, call the pharmacy before drawing.

Step-by-step: drawing 2.5 mg with a U-100 insulin syringe

This protocol assumes a pre-mixed vial at 10 mg/mL concentration and a 0.5 mL U-100 insulin syringe with 31-gauge, 5/16-inch needle. Adjust unit count using the chart above for other concentrations.

Materials checklist:

• Compounded semaglutide or tirzepatide vial (refrigerated until use)
• U-100 insulin syringe, unopened package
• Two alcohol prep pads
• Sharps disposal container
• Clean, flat work surface

Preparation (30 seconds):

1. Remove the vial from refrigeration 10 minutes before injection. Cold medication stings more on injection. Room temperature is fine for the brief time needed to draw and inject.
2. Wash hands with soap and water for 20 seconds. Dry completely.
3. Inspect the vial. Hold it up to light. Semaglutide and tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unusual color (pink, orange, brown) means the vial is compromised. Don't use it.
4. Check the concentration on the label. Confirm it matches what you expect. If this is a new vial or a refill from a different pharmacy, recalculate your unit count before proceeding.

Drawing the dose (60 seconds):

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or wipe it dry.
2. Open the syringe package. Don't touch the needle. If the needle touches anything other than the vial stopper or your skin, discard the syringe and start with a new one.
3. Pull the plunger back to 25 units (for a 2.5 mg dose at 10 mg/mL). This draws air into the syringe equal to the volume you'll withdraw.
4. Insert the needle through the vial stopper. Push straight down. The stopper has a center target area that self-seals after puncture.
5. Push the plunger to inject 25 units of air into the vial. This equalizes pressure and makes drawing easier.
6. Invert the vial so the needle tip is submerged in liquid. Keep the needle in the vial.
7. Pull the plunger back slowly to 25 units. Watch the liquid level. If you see air bubbles, stop pulling and tap the syringe barrel sharply to dislodge them. Push the liquid (and bubbles) back into the vial, then re-draw.
8. Double-check the measurement. Hold the syringe at eye level. The plunger's black rubber tip (the end closest to the needle) should align exactly with the 25-unit line. If you're between markings, push excess back into the vial until aligned.
9. Remove the needle from the vial. Pull straight out. Set the vial aside (don't recap the needle).

Injection (30 seconds):

1. Choose an injection site. Subcutaneous sites for GLP-1 medications: abdomen (2 inches away from navel), front or outer thigh, or back of upper arm. Rotate sites weekly to prevent lipohypertrophy (tissue thickening).
2. Wipe the injection site with the second alcohol pad. Let it air-dry.
3. Pinch a fold of skin between thumb and forefinger. Insert the needle at a 90-degree angle (straight in) with a quick motion. If you have very little subcutaneous fat, use a 45-degree angle.
4. Push the plunger steadily until the syringe is empty. Count to three.
5. Release the skin fold, then withdraw the needle. Pull straight out. Don't rub the injection site.
6. Apply light pressure with a clean tissue if there's a drop of blood (rare). A small amount of medication leaking back out is normal and doesn't affect the dose.
7. Dispose of the syringe immediately in a sharps container. Never recap. Never reuse.

Total time: 2 minutes for an experienced patient, 4 to 5 minutes when learning.

What most articles get wrong about "units"

Most online guides treat "units" as if it's a property of the medication. You'll see phrases like "semaglutide is dosed in units" or "2.5 mg equals 25 units." Both are wrong.

A unit is a measure of insulin's biological activity, defined by the International Unit system. The insulin unit was originally defined in the 1920s by its biological effect on blood glucose. Insulin syringes are called "U-100" because they're calibrated for insulin at 100 units per mL.

Semaglutide and tirzepatide are not insulin. They have no unit-based potency. When a pharmacy writes "draw 25 units," they mean "draw to the 25-unit marking on a U-100 insulin syringe," which corresponds to 0.25 mL of liquid. The instruction is about syringe markings, not medication units.

This distinction matters because:

1. It explains why the unit count changes with concentration. If "units" were a property of the medication, 2.5 mg would always be the same number of units. But it's not. It's 25 units at 10 mg/mL and 50 units at 5 mg/mL because the volume changes.

2. It prevents errors when switching syringe types. A patient who thinks "I take 25 units of semaglutide" might draw to the 25-unit mark on a U-40 syringe (used for veterinary insulin) and get 2.5x the intended dose. The correct mental model is "I take 0.25 mL of semaglutide, which is 25 markings on a U-100 syringe."

3. It clarifies why you can't use tuberculin syringes interchangeably. Tuberculin syringes are marked in 0.01 mL increments but don't have "unit" markings. A patient told to "draw 25 units" with a tuberculin syringe doesn't know where to stop unless they convert to 0.25 mL first.

The insulin syringe convention exists because U-100 syringes are cheap, widely available, and have small enough markings for the tiny doses GLP-1 medications require. There's no separate "semaglutide syringe" on the market. So pharmacies adopted insulin syringe language, and the terminology stuck.

Correction, September 2026: an earlier version cited a 2024 study of 890 patients (Martinez et al.) finding 40 percent fewer errors with milliliter-based instructions. That study could not be found in PubMed and has been removed. Thinking in milliliters is still a useful habit, because it forces you to notice which syringe scale you are holding.

The three failure modes of syringe-based dosing

Three recurring error patterns show up in self-administered compounded GLP-1 therapy. Each has a different root cause and requires a different intervention. Correction, September 2026: an earlier version attached percentages to each pattern from an internal dataset; those figures have been removed.

Failure Mode 1: Concentration mismatch. Patient continues drawing the same unit count after switching to a vial with different concentration. Example: Patient draws 25 units (correct for 10 mg/mL) from a new 5 mg/mL vial, receiving 1.25 mg instead of 2.5 mg.

Prevention: Write the unit count on the vial box in permanent marker when you receive it. Before each injection, confirm the unit count matches the concentration. If the vial looks different, re-check.

Failure Mode 2: Syringe misidentification. Patient uses a non-U-100 syringe (typically U-40 or U-500) and draws to the printed unit count, receiving 2.5x or 0.2x the intended dose.

Prevention: Confirm "U-100" is printed on the syringe barrel before opening the package. U-100 syringes are the only type that should be used for compounded GLP-1 medications unless your pharmacy provides a different syringe with specific instructions.

Failure Mode 3: Reconstitution volume error. Patient adds the wrong amount of bacteriostatic water to lyophilized powder, changing the final concentration. Example: Instructions say "add 2 mL water to make 5 mg/mL," but patient adds 3 mL, creating a 3.33 mg/mL solution. Drawing 50 units delivers 1.67 mg instead of 2.5 mg.

Prevention: Reconstitute over a clean surface with good lighting. Measure bacteriostatic water in a separate syringe before adding to the vial. If you're unsure about the volume, contact the pharmacy before proceeding.

Other errors are miscellaneous: drawing to the wrong line, misreading fractional units, injecting air instead of medication.

When 2.5 mg isn't actually 2.5 mg (reconstitution errors)

Some compounding pharmacies ship semaglutide and tirzepatide as lyophilized powder in a vial, with bacteriostatic water in a separate vial or pre-filled syringe. You reconstitute (mix) the powder immediately before first use. The concentration depends on how much water you add.

Standard reconstitution instructions look like this:

> "Add 2.0 mL of bacteriostatic water to the vial containing 10 mg semaglutide powder. Gently swirl (do not shake) until fully dissolved. Final concentration: 5 mg/mL. Draw 50 units (0.5 mL) for a 2.5 mg dose."

If you add 3 mL of water instead of 2 mL, the concentration becomes 10 mg ÷ 3 mL = 3.33 mg/mL. Drawing 50 units now delivers only 1.67 mg, not 2.5 mg. You've under-dosed by 33%.

The opposite error (adding too little water) is less common because bacteriostatic water is usually supplied in pre-measured amounts. But if you're using a separate water vial and drawing freehand, over-concentration is possible.

How to reconstitute without error:

1. Read the reconstitution instructions twice before opening any vials. Note the exact water volume required.
2. Use a separate syringe to measure bacteriostatic water. Draw the specified volume (e.g., 2.0 mL) into a 3 mL syringe. Confirm the measurement at eye level.
3. Inject the water slowly into the powder vial. Aim the stream at the vial wall, not directly at the powder. This prevents foaming.
4. Swirl gently for 30 seconds. Don't shake. Shaking can denature peptides and create bubbles that make accurate dosing harder.
5. Wait 2 minutes for complete dissolution. The solution should be clear with no visible particles. If particles remain, swirl for another 30 seconds.
6. Label the vial with reconstitution date and final concentration. Use a permanent marker or pre-printed label. Include "Use by [date 28 days from now]."

Correction, September 2026: an earlier version cited a 2023 Diabetes Technology and Therapeutics study (Thompson et al.) with 11, 3 and 0.8 percent error figures for reconstitution. That study could not be found in PubMed and has been removed.

If your pharmacy ships powder for reconstitution, request a pre-filled bacteriostatic water syringe. It eliminates the measurement step.

U-100 vs. U-40 vs. U-500: why syringe type matters more than you think

Insulin syringes come in three concentrations, each calibrated for a different insulin formulation:

• U-100 syringes: 100 units per mL (1 unit = 0.01 mL). Used for U-100 insulin (Humalog, Novolog, Lantus, etc.). This is the standard for compounded GLP-1 medications.
• U-40 syringes: 40 units per mL (1 unit = 0.025 mL). Used for U-40 veterinary insulin and some international human insulin formulations.
• U-500 syringes: 500 units per mL (1 unit = 0.002 mL). Used for U-500 concentrated insulin (Humulin R U-500). Correction, September 2026: an earlier version printed 0.005 mL here; 1 mL divided by 500 units is 0.002 mL.

The syringe type must match the medication concentration. Using the wrong syringe creates a dosing error proportional to the ratio of the two unit scales.

Example: Drawing 25 units of 10 mg/mL semaglutide with different syringes

• U-100 syringe (correct): 25 units = 0.25 mL = 2.5 mg ✓
• U-40 syringe (wrong): 25 units = 0.625 mL = 6.25 mg (2.5x overdose)
• U-500 syringe (wrong): 25 units = 0.05 mL = 0.5 mg (0.2x underdose)

U-100 and U-40 syringes look nearly identical. Both have "unit" markings. Both fit standard vial stoppers. The only visual difference is the printed label on the barrel. A patient in a hurry can easily grab the wrong syringe from a drawer.

How to confirm you have a U-100 syringe:

1. Check the barrel label. It should say "U-100" or "100 units per mL" near the plunger.
2. Check the package. The box or wrapper should say "U-100 insulin syringe."
3. Count the markings. A 0.5 mL U-100 syringe has 50 unit markings between 0 and 0.5 mL. A 0.5 mL U-40 syringe has only 20 unit markings in the same space.

If you're unsure, don't use the syringe. Order confirmed U-100 syringes from a pharmacy or medical supply company.

Correction, September 2026: an earlier version stated that the FDA had received 47 reports of U-40/U-100 confusion and 12 emergency visits between January 2024 and March 2025. We could not reproduce that count from any FDA publication, and it has been removed. The FDA's page on compounded GLP-1 products says only that it has received reports of adverse events that may be related to dosing errors (content current as of September 1, 2026).

Storage and stability after first draw

Unopened vials: Store at 36 to 46°F (2 to 8°C) in the refrigerator. Don't freeze. Freezing denatures peptides and makes the medication ineffective. If a vial freezes accidentally, discard it.

After first puncture: Most compounding pharmacies label vials "use within 28 days of first puncture" or "discard 28 days after opening." This is a USP <797> standard for multi-dose vials containing preservatives (typically benzyl alcohol or metacresol). Some pharmacies use a 21-day window. Follow the date on your specific vial label.

Room temperature exposure: follow the beyond-use and temperature instructions on your pharmacy label. For comparison, the approved products carry label limits: a Zepbound single-dose pen or vial may be kept at room temperature up to 86°F for a total of 21 days, and a multi-dose vial or KwikPen 30 days (Zepbound label, September 2026). No published stability study covers compounded semaglutide or tirzepatide. Correction, September 2026: an earlier version cited a 2023 stability study (Nguyen et al.) and a 24-hour rule; the study could not be found in PubMed, and both have been removed.

Travel: Use an insulated medication bag with a reusable ice pack (not direct ice). Direct contact with ice can freeze the vial. If you're traveling for more than 24 hours, request a travel-size cooler from your pharmacy or buy a medical-grade insulin cooler (brands like FRIO or MedAngel).

Color changes: Clear to faint yellow is normal. Pink, red, or orange tint usually indicates added vitamin B12 (cyanocobalamin), which some pharmacies add. If your vial is colored and the label doesn't mention B12, call the pharmacy. Brown or dark yellow suggests oxidation or contamination. Don't use it.

Cloudiness or particles: Never use a cloudy vial or one with visible floating particles. Peptides can aggregate if temperature-cycled or exposed to light. Aggregated peptide is less effective and potentially more immunogenic (more likely to trigger antibody formation).

When to contact your provider about dose conversion

Contact your prescribing provider within 24 hours if:

1. You drew or injected a significantly different dose than prescribed. "Significantly different" means more than 20% off target. Example: You intended 2.5 mg (25 units at 10 mg/mL) but drew 50 units, delivering 5 mg. Small errors (23 units instead of 25 units) are usually clinically irrelevant.

2. You experience severe or persistent side effects after a dose. Severe nausea lasting more than 12 hours, repeated vomiting (more than three episodes), severe abdominal pain, signs of pancreatitis (pain radiating to the back, fever), or signs of gallbladder issues (right upper quadrant pain, jaundice).

3. You're unsure about your vial's concentration and can't reach the pharmacy. Don't guess. If the pharmacy is closed and you can't verify concentration, skip the dose and contact your provider in the morning. Missing one weekly dose has minimal impact on efficacy.

4. You switched pharmacies and the new vial's concentration is different. Your provider may need to rewrite dosing instructions in units that match the new concentration.

5. You have signs of an allergic reaction. Hives, swelling of the face or throat, difficulty breathing, rapid heartbeat. This is rare but requires immediate medical attention (call 911, don't wait for a callback).

Most small dosing errors (drawing 27 units instead of 25 units) are unlikely to matter, but whether a given deviation matters is your prescriber's judgment, not a fixed rule.

What 2.5 mg looks like in the approved products

If you searched for how many units 2.5 mg of Zepbound is, the answer is that you normally do not draw it. The Zepbound label (September 2026) supplies 2.5 mg as a single-dose pen that injects automatically, or as a single-dose vial containing 2.5 mg in 0.5 mL: the label's instructions say to draw the full 0.5 mL, which is 50 units on a U-100 syringe. The multi-dose vial and KwikPen hold 2.4 mL for four weekly 0.6 mL doses at six strengths (10, 20, 30, 40, 50 and 60 mg per 2.4 mL, or 4.17 to 25 mg/mL). Wegovy pens deliver fixed doses of 0.25 to 2.4 mg, and a 7.2 mg pen and daily tablets were added by the June 2026 label. The unit arithmetic on this page applies only to compounded vials, where you set the volume yourself.

Syringe scales side by side

The same "25 units" marking delivers a different volume on each insulin syringe type. Numbers below are arithmetic (1 mL divided by the units printed per mL).

Syringe	Volume per unit	25 units equals	2.5 mg at 10 mg/mL would deliver
U-100 (correct for compounded GLP-1s)	0.01 mL	0.25 mL	2.5 mg
U-40 (veterinary insulin)	0.025 mL	0.625 mL	6.25 mg (2.5 times the dose)
U-500 (concentrated insulin)	0.002 mL	0.05 mL	0.5 mg (one-fifth of the dose)

Check the barrel for "U-100" before every draw. If your pharmacy supplies a different syringe with its own instructions, follow those instructions and nothing on this page.

FDA status and safety reports as of September 5, 2026

The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the Fifth Circuit upheld the tirzepatide decision on August 27, 2026; compounded copies are now permitted only for a documented individual clinical need. The FDA's page on unapproved GLP-1 drugs (content current as of September 1, 2026) reports 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, says some may be related to dosing errors, and notes warning letters to firms selling these peptides labeled "for research purposes." Only a vial dispensed by a licensed pharmacy under a prescription carries a concentration you can trust, and current compounded pricing is tracked in the Compounded GLP-1 Price Index.

FAQ

How many units is 2.5 mg on an insulin syringe?

At 10 mg/mL concentration, 2.5 mg equals 25 units on a U-100 insulin syringe. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The unit count depends on your vial's concentration, which is printed on the label.

What does "U-100" mean on an insulin syringe?

U-100 means the syringe is calibrated for insulin at 100 units per milliliter. Each unit marking represents 0.01 mL. For compounded GLP-1 medications, U-100 syringes are the standard because they provide small enough increments for accurate dosing.

Can I use a tuberculin syringe instead of an insulin syringe?

Tuberculin syringes are marked in milliliters (0.01 mL increments) but don't have unit markings. You can use one if you convert your dose to milliliters first. For 2.5 mg at 10 mg/mL, draw to the 0.25 mL line. Most patients find insulin syringes easier because pharmacy instructions are written in units.

What if my dose falls between unit markings?

U-100 insulin syringes with 0.3 mL or 0.5 mL barrels have half-unit markings (0.5, 1.5, 2.5, etc.). If your dose is 12.5 units, draw to the halfway point between 12 and 13. If your syringe doesn't have half-unit markings and your dose requires one, request a syringe with finer graduations from your pharmacy.

How do I know if I have a U-100 syringe?

Check the barrel label. It should say "U-100" or "100 units/mL." The package should also specify U-100. If there's no label, count the markings: a 1 mL U-100 syringe has 100 unit markings between 0 and 1 mL.

What happens if I accidentally use a U-40 syringe?

Drawing 25 units on a U-40 syringe delivers 0.625 mL instead of 0.25 mL, giving you 2.5x the intended dose. If you realize the error before injecting, discard the syringe and start over with a U-100 syringe. If you already injected, contact your provider and monitor for increased side effects (nausea, vomiting, diarrhea).

Can I reuse insulin syringes for multiple doses?

No. Insulin syringes are single-use only. Reusing dulls the needle (making injections more painful), increases infection risk, and can introduce contamination into the vial. The savings are tiny and the risk isn't worth it.

Why does my pharmacy use a different concentration than my friend's pharmacy?

Compounding pharmacies choose concentrations based on vial size, total medication amount, and patient population. There's no regulatory standard. Some optimize for clean math (10 mg/mL), others for small injection volume (20 mg/mL), and others for vial longevity (5 mg/mL in larger vials).

How do I convert my dose if I switch from brand-name to compounded medication?

Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) use pre-filled pens with fixed doses. The pen delivers the dose automatically. When switching to compounded medication, your provider prescribes the same milligram dose, and you draw that dose in units based on your vial's concentration. Example: a 0.5 mg dose is 20 units at 2.5 mg/mL or 10 units at 5 mg/mL, two concentrations commonly listed for compounded semaglutide.

What's the smallest dose I can accurately draw with a U-100 syringe?

U-100 syringes with half-unit markings can measure as low as 0.5 units (0.005 mL). For compounded GLP-1 medications, this corresponds to 0.05 mg at 10 mg/mL. Doses below 2 units are difficult to draw accurately because the markings are very close together.

Do I need to remove air bubbles from the syringe?

Yes. Air bubbles displace medication and reduce the dose. Small bubbles (1 to 2 units worth) cause minor under-dosing. Large bubbles (10+ units) can cut the dose significantly. Tap the syringe sharply to dislodge bubbles, push them back into the vial, and re-draw.

How long does a vial last at 2.5 mg per week?

A 10 mg vial at 10 mg/mL contains four 2.5 mg doses (one month supply). A 30 mg vial contains twelve doses (three months supply). Vials expire 28 days after first puncture, so a 30 mg vial used at 2.5 mg weekly will expire before you use all the medication. Most pharmacies dispense 10 mg or 20 mg vials for the 2.5 mg dose to minimize waste.

How many units is 2.5 mg of Zepbound?

For the approved product you usually do not measure it: the 2.5 mg Zepbound pen injects the dose automatically, and the 2.5 mg single-dose vial contains 0.5 mL, all of which is drawn, equal to 50 units on a U-100 syringe (Zepbound label, September 2026). Only compounded vials require you to calculate units from the concentration on the label, using dose divided by mg/mL times 100.

Has the FDA said anything about dosing errors with compounded GLP-1 medicines?

Yes. Its page on unapproved GLP-1 drugs, current as of September 1, 2026, says the agency has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. As of May 31, 2026 it counted 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. It does not publish a breakdown by cause, so any percentage you see attributed to the FDA is not from the FDA.

Are compounded semaglutide and tirzepatide still legal to buy?

In limited circumstances. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and semaglutide on February 21, 2025, and the tirzepatide decision was upheld on appeal on August 27, 2026. Outside a shortage, a compounding pharmacy may prepare a copy of an approved drug only for a documented individual clinical need under a valid prescription. Products sold online as research chemicals are unapproved drugs, and the FDA has issued warning letters to their sellers.

Related guides

• Sermorelin Dosage in Units: How to Convert Micrograms to Insulin Syringe Markings
• Semaglutide Dosage Chart Units: How to Convert Milligrams to Syringe Markings at Any Concentration
• Tirzepatide Dosing Calculator: How to Convert Any Dose to Syringe Units Accurately
• The Complete Semaglutide Dose Chart: Milligrams, Milliliters, and Insulin Syringe Units
• Insulin Syringe Units To Ml Guide
• Sermorelin Dosage Chart: How to Convert mcg to Units for Every Vial Concentration
• Tool: dosage calculator

Sources

1. United States Pharmacopeia Chapter <797>. Pharmaceutical Compounding - Sterile Preparations. 2024 revision.
2. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
9. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (dosing-error statement; adverse-event counts as of May 31, 2026). Content current as of September 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
10. DailyMed (NIH). Zepbound (tirzepatide) prescribing information: section 3 strengths, vial instructions, section 16.2 storage. Published September 2, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
11. DailyMed (NIH). Wegovy (semaglutide) prescribing information: section 2 dosage forms and escalation. Published June 30, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
12. U.S. Food and Drug Administration. Tirzepatide shortage resolution notice, December 19, 2024. https://www.fda.gov/media/185577/download
13. Rivas Weight Loss. GLP-1 dose calculator (typical semaglutide 2.5 and 5 mg/mL; tirzepatide 17 and 20 mg/mL). Updated March 2026. https://www.rivasweightloss.com/glp1-dose-calculator/
14. The Medicine Shoppe, Victor, New York. Injectable tirzepatide patient sheet, 10 mg/mL. October 2024. https://compoundingrochester.com/wp-content/uploads/2024/10/Injectable_Tirzepatide_incl_chart_Victor.pdf
15. FormBlends. Compounded GLP-1 Price Index data feed. As of September 3, 2026. https://formblends.com/feeds/glp1-prices.json

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Humalog, Novolog, Lantus, and Humulin are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "How many units is 2.5 mg on an insulin syringe?", "acceptedAnswer": { "@type": "Answer", "text": "At 10 mg/mL concentration, 2.5 mg equals 25 units on a U-100 insulin syringe. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The unit count depends on your vial's concentration, which is printed on the label." } }, { "@type": "Question", "name": "What does U-100 mean on an insulin syringe?", "acceptedAnswer": { "@type": "Answer", "text": "U-100 means the syringe is calibrated for insulin at 100 units per milliliter. Each unit marking represents 0.01 mL. For compounded GLP-1 medications, U-100 syringes are the standard because they provide small enough increments for accurate dosing." } }, { "@type": "Question", "name": "Can I use a tuberculin syringe instead of an insulin syringe?", "acceptedAnswer": { "@type": "Answer", "text": "Tuberculin syringes are marked in milliliters (0.01 mL increments) but don't have unit markings. You can use one if you convert your dose to milliliters first. For 2.5 mg at 10 mg/mL, draw to the 0.25 mL line. Most patients find insulin syringes easier because pharmacy instructions are written in units." } }, { "@type": "Question", "name": "What if my dose falls between unit markings?", "acceptedAnswer": { "@type": "Answer", "text": "U-100 insulin syringes with 0.3 mL or 0.5 mL barrels have half-unit markings (0.5, 1.5, 2.5, etc.). If your dose is 12.5 units, draw to the halfway point between 12 and 13. If your syringe doesn't have half-unit markings and your dose requires one, request a syringe with finer graduations from your pharmacy." } }, { "@type": "Question", "name": "How do I know if I have a U-100 syringe?", "acceptedAnswer": { "@type": "Answer", "text": "Check the barrel label. It should say U-100 or 100 units/mL. The package should also specify U-100. If there's no label, count the markings: a 1 mL U-100 syringe has 100 unit markings between 0 and 1 mL." } }, { "@type": "Question", "name": "What happens if I accidentally use a U-40 syringe?", "acceptedAnswer": { "@type": "Answer", "text": "Drawing 25 units on a U-40 syringe delivers 0.625 mL instead of 0.25 mL, giving you 2.5x the intended dose. If you realize the error before injecting, discard the syringe and start over with a U-100 syringe. If you already injected, contact your provider and monitor for increased side effects." } }, { "@type": "Question", "name": "Can I reuse insulin syringes for multiple doses?", "acceptedAnswer": { "@type": "Answer", "text": "No. Insulin syringes are single-use only. Reusing dulls the needle (making injections more painful), increases infection risk, and can introduce contamination into the vial. The savings are tiny and the risk isn't worth it." } }, { "@type": "Question", "name": "Why does my pharmacy use a different concentration than my friend's pharmacy?", "acceptedAnswer": { "@type": "Answer", "text": "Compounding pharmacies choose concentrations based on vial size, total medication amount, and patient population. There's no regulatory standard. Some optimize for clean math (10 mg/mL), others for small injection volume (20 mg/mL), and others for vial longevity (5 mg/mL in larger vials)." } }, { "@type": "Question", "name": "How do I convert my dose if I switch from brand-name to compounded medication?", "acceptedAnswer": { "@type": "Answer", "text": "Brand-name semaglutide and tirzepatide use pre-filled pens with fixed doses. When switching to compounded medication, your provider prescribes the same milligram dose, and